Nasopharyngeal Carcinoma: all 824 studies

Page 5 of 9. Open to participants first (281), then studies with results posted, then the rest; newest registration first within each.

• To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal CancerStatus unknownNCT05198531Phase 1/2
• Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-inSuspendedNCT05198479Phase 2
• Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT05193617Phase 2
• Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT05162872Phase 2
• Olfactory Change After Chemo-radiotherapy for Nasopharyngeal CarcinomaStatus unknownNCT05146050
• Optimization of Cervical Nodal CTV for Early and Medium Stage NPCActive, not recruitingNCT05145660Phase 3
• A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Phase 2
• Prognostic Prediction of NPC Based on MR Diffusion-weighted ImagingStatus unknownNCT05112510
• Asian Multicenter Prospective Study of ctDNA SequencingActive, not recruitingNCT05099978
• Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal CarcinomaStatus unknownNCT05092217Phase 2
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersActive, not recruitingNCT05063552Phase 2/3
• Verification of Harmonization of Plasma Epstein-Barr Virus DNA MeasurementsStatus unknownNCT05037357
• SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT05020925Phase 1/2
• Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated RadiotherapyCompletedNCT05020067Phase 2
• Application of Whole-course Standardized Nutrition Management During Peri-radiotherapy in Patients With Nasopharyngeal Carcinoma After Radiotherapy: a Multicenter Randomized Controlled Clinical StudyStatus unknownNCT05008471Not applicable
• Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)CompletedNCT04996758Phase 2
• 18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning StudyCompletedNCT04995185Not applicable
• Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II TrialStatus unknownNCT04992988Phase 2
• A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Phase 3
• Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04955886Phase 2
• The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNCCompletedNCT04929080Phase 1/2
• Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative StudiesActive, not recruitingNCT04925544Phase 2
• Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT04921995Phase 2
• The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04917770Phase 2
• PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaActive, not recruitingNCT04907370Phase 3
• A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal CarcinomaCompletedNCT04895345Phase 2
• Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II StudyStatus unknownNCT04872582Phase 2
• Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck CancerCompletedNCT04870840Phase 1
• Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation StudyActive, not recruitingNCT04850235Phase 1
• Nedaplatin in Treatment for Nasopharyngeal CarcinomaCompletedNCT04834206Phase 2
• Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPCCompletedNCT04833257Phase 2
• Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal CancerActive, not recruitingNCT04825990Phase 2
• Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal CarcinomaCompletedNCT04823468Not applicable
• Early Nutritional Intervention in NPC Patients Undergoing Concurrent ChemoradiotherapyStatus unknownNCT04810936Not applicable
• Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal CarcinomaStatus unknownNCT04764149
• Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPCStatus unknownNCT04745741
• A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal CarcinomaCompletedNCT04736810Phase 2
• OPHTHALMOLOGIC EVALUATION OF RADIATION-RELATED OPTIC NEUROPATHY FOLLOWING IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY (IMRT) FOR NASOPHARYNGEAL CARCİNOMAStatus unknownNCT04724590Not applicable
• Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal CarcinomaCompletedNCT04636632Phase 1
• A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04627961Phase 2
• Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment FailureActive, not recruitingNCT04586088Phase 2
• Treatment of Bevacizumab Followed by Steroid in RNStatus unknownNCT04553510Phase 2
• Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04548271Phase 2
• Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04547088Phase 2
• Randomized Trial to Evaluate Accelerated Radiotherapy in Locally Advanced Carcinoma of NasopharynxStatus unknownNCT04538547Not applicable
• Proton Versus Photon Radiotherapy for Nasopharyngeal CarcinomaCompletedNCT04528394Phase 2
• Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04517214Phase 2
• EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal CarcinomaCompletedNCT04509726Phase 1/2
• Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction ChemotherapyCompletedNCT04508816Phase 2
• Saliva Substitute Mouthwash in NPC Survivors With Xerostomia: A Randomized Controlled TrialCompletedNCT04491435Not applicable
• A Study of DC-CIK Immunotherapy in the Treatment of Solid TumorsStatus unknownNCT04476641Phase 2
• Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04472403
• Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal CarcinomaActive, not recruitingNCT04456322Phase 3
• Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT04447612Phase 2
• Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT04446663Phase 2
• Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPCStatus unknownNCT04421469Phase 2
• To Evaluate Transoral Flexible Endoscope With Narrow Band Imaging in Nasopharyngeal CancerStatus unknownNCT04419324Not applicable
• Prognostic Utility of the Imaging and Biological Signatures in Nasopharyngeal CarcinomaCompletedNCT04417985Not applicable
• Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.Status unknownNCT04405622Phase 2
• Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04398056Phase 2
• Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPCCompletedNCT04396886Phase 2
• Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma PatientsStatus unknownNCT04394091
• uEXPLORER Total-body PET/CT in Nasopharyngeal CarcinomaCompletedNCT04394065
• To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPCCompletedNCT04387266
• Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent ChemoradiotherapyActive, not recruitingNCT04384627Phase 3
• Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaCompletedNCT04350190Phase 2
• Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal CarcinomaStatus unknownNCT04319471Phase 2
• The Association of hsCRP and Radiotherapy-Induced Toxicity in Patients With Nasopharyngeal CarcinomaStatus unknownNCT04303975
• Comparison of Transdermal Fentanyl and Morphine for Oral Mucositis Pain in Nasopharyngeal Cancer PatientsStatus unknownNCT04292990Phase 4
• SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04282070Phase 1
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsTerminatedNCT04272034Phase 1
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsCompletedNCT04242199Phase 1
• Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal CancerWithdrawnNCT04231864Phase 2
• Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaCompletedNCT04227509Phase 2
• Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal CarcinomaActive, not recruitingNCT04223024Phase 2
• Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPCStatus unknownNCT04220528Phase 2
• A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal CarcinomaCompletedNCT04220307Phase 2
• Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04215978Phase 1
• De-escalation Protocols in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT04158518Not applicable
• Applying PET/MR in Oncology - a Prospective ProjectStatus unknownNCT04158414Not applicable
• Prospective Comparisons of Clinical Trial and Real-world Outcomes in Nasopharyngeal CarcinomaCompletedNCT04108338
• Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid TumourStatus unknownNCT04107142Phase 1
• Intestinal Flora Sequencing for Nasopharyngeal CarcinomaCompletedNCT04094545
• Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.Status unknownNCT04073784Phase 1
• EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)Active, not recruitingNCT04072107Phase 2
• A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma PatientsStatus unknownNCT04061278Phase 3
• The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT04028479
• Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPCStatus unknownNCT04015661Phase 2
• The Prognostic Value of Human Papilloma Virus in Nasopharyngeal CarcinomaStatus unknownNCT04014738
• Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal CarcinomaCompletedNCT04004871Phase 2
• PD-L1 and BRAF Expression in Nasopharyngeal CarcinomaCompletedNCT03989297
• Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaCompletedNCT03984357Phase 2
• The Value of Post-radiation Detectable Plasma EBV DNA in High-risk Nasopharyngeal Carcinoma PatientsCompletedNCT03981224
• Plasma EBV DNA Monitoring in Post-treatment NPC PatientsCompletedNCT03973723
• Cell-free Tumor DNA in Head and Neck Cancer PatientsStatus unknownNCT03942380Not applicable
• Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal CarcinomaStatus unknownNCT03932266Phase 2
• Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal CarcinomaActive, not recruitingNCT03930498Phase 2
• Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC PatientsStatus unknownNCT03925896Phase 1
• Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC PatientsActive, not recruitingNCT03925090Phase 2
• Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related TumoursStatus unknownNCT03923842Phase 2

← Nasopharyngeal Carcinoma overview